A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects With Autism Spectrum Disorder
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Nov 2019 Planned primary completion date changed from 17 Feb 2021 to 2 Aug 2021.
- 20 Sep 2019 Planned End Date changed from 3 Mar 2021 to 2 Aug 2021.
- 16 Nov 2018 Status changed from not yet recruiting to recruiting.